GLP-1s: Worth the Hype?

The 2022 framing is interesting - the clinical picture has gotten much clearer since then as real-world data scaled up. The early discussion was largely theoretical benefits whereas now you have actual outcome data from millions of patients. The short answer to 'does it live up to the hype' is mostly yes, with the caveat that individual response varies more than the averages suggest.

The hype vs reality question has a more interesting answer now that you have years of real-world data to look at - the average results in clinical trials have largely held up in practice, and the safety profile has been better than expected at scale. Individual variation is wider than the averages suggest and that's the honest caveat.

The effort argument about these medications misses that lifestyle changes are still happening alongside the medication. People taking steps on tired days, tracking food, cutting habits that were years old - that's all still effort. The medication doesn't replace any of that work, it just makes the starting conditions more equal.

the trajectory from single to triple agonist in a relatively short development window is the part that makes the next-generation projections plausible rather than speculative - the compounds that would have seemed unlikely five years ago are now in trials. the clinical experience at each generation has informed the design of the next, and the indication breadth expands with each step up in receptor coverage